FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
申请人:Shigeta Yukihiro
公开号:US20120209005A1
公开(公告)日:2012-08-16
Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided.
A compound represented by the formula (I) (wherein R
1
is an aryl group fused to a saturated ring or the like, A, B, L
1
, R
2
, L
2
, L
3
, Y, L
4
, R
3
and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.
their reactivity in [2+2+2] cycloaddition reactions compared with highly active [CpCo(H2CCHSiMe3)2] (1). Whereas 1 is an excellent precursor for the synthesis of [CpCo(olefin)(phosphite)] complexes (2 a–f), [CpCo(phosphite)2] complexes (3 a–e) were prepared photochemically from [CpCo(cod)]. The complexes were evaluated in the cyclotrimerization reaction of diynes with nitriles yielding pyridines. For
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.